GANX

2.41

5.49% -0.14

Dopo l'orario di chiusura: 2.40 -0.01 -0.41%

Gain Therapeutics Inc (GANX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché GANX Giù? Forum Previsione

Precedente Chiudi:

$2.55

Aprire:

$2.62

Volume 24 ore:

1.51M

Relative Volume:

1.05

Capitalizzazione di mercato:

$92.69M

Reddito:

$210.70K

Utile/perdita netta:

$-21.37M

Rapporto P/E:

-2.1909

EPS:

-1.1

Flusso di cassa netto:

$-21.10M

1 W Prestazione:

-25.16%

1M Prestazione:

-37.40%

6M Prestazione:

+50.62%

1 anno Prestazione:

+6.17%

Intervallo 1D:

$2.34

$2.71

Intervallo di 1 settimana:

$2.30

$3.29

Portata 52W:

$1.41

$4.34

Gain Therapeutics Inc Stock (GANX) Company Profile

Nome

Gain Therapeutics Inc

Settore

Healthcare (1116)

Industria

Biotechnology (620)

Telefono

(301) 500-1556

Indirizzo

4800 HAMPDEN LANE, BETHESDA

Dipendente

Cinguettio

Prossima data di guadagno

2025-03-26

Ultimi documenti SEC

GANX's Discussions on Twitter

Confronta GANX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
GANX Gain Therapeutics Inc	2.41	98.08M	210.70K	-21.37M	-21.10M	-1.10
VRTX Vertex Pharmaceuticals Inc	484.15	118.84B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	812.27	81.61B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	422.50	53.69B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	822.94	49.49B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	176.00	37.34B	447.02M	-1.18B	-906.14M	-6.1812

Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-03-07	Iniziato	Scotiabank	Sector Outperform
2024-12-06	Iniziato	ROTH MKM	Buy
2024-08-14	Ripresa	Oppenheimer	Outperform
2021-04-12	Iniziato	BTIG Research	Buy
2021-04-12	Iniziato	Oppenheimer	Outperform

Gain Therapeutics Inc Borsa (GANX) Ultime notizie

07:15 AM

Gain Therapeutics, Inc. to Participate in Key Events During 44th Annual J.P. Morgan Healthcare Conference Week - Quiver Quantitative

07:15 AM

07:00 AM

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week - Yahoo Finance

07:00 AM

Jan 06, 2026

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Jan 06, 2026

GANX: GT-02287 reduced GluSph by 81% and improved motor scores in Parkinson's disease patients - TradingView — Track All Markets

Jan 06, 2026

Gain Therapeutics reports 81% reduction in Parkinson’s biomarker By Investing.com - Investing.com Australia

Jan 06, 2026

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 - The Manila Times

Jan 06, 2026

Jan 05, 2026

Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Benzinga

Jan 05, 2026

Jan 02, 2026

Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Jan 02, 2026

Dec 28, 2025

Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update - MarketBeat

Dec 28, 2025

Dec 25, 2025

Research Analysts’ Weekly Ratings Changes for Gain Therapeutics (GANX) - Defense World

Dec 25, 2025

Dec 23, 2025

Roth/MKM raises Gain Therapeutics stock price target to $10 on positive trial data - Investing.com Australia

Dec 23, 2025

Dec 22, 2025

Gain Therapeutics (GANX) Upgraded to Buy: Here's Why - Yahoo Finance

Dec 22, 2025

Roth/MKM raises Gain Therapeutics stock price target to $10 on positive trial data By Investing.com - Investing.com South Africa

Dec 22, 2025

Dec 21, 2025

Gain Therapeutics Sees Stock Surge Amid Positive Clinical Results and Ambitious Price Target Increase - StocksToTrade

Dec 21, 2025

Is Gain Therapeutics Inc. stock a smart buy before Fed meeting2025 Investor Takeaways & Expert Curated Trade Setup Alerts - Улправда

Dec 21, 2025

Dec 20, 2025

Gain Therapeutics (GANX) Price Target Increased by 11.76% to 7.75 - Nasdaq

Dec 20, 2025

Gain Therapeutics’ (GANX) Buy Rating Reaffirmed at HC Wainwright - Defense World

Dec 20, 2025

Can Gain Therapeutics Inc. stock reach $100 price target2025 Major Catalysts & Risk Managed Trade Strategies - Улправда

Dec 20, 2025

Dec 19, 2025

HC Wainwright & Co. Reiterates Gain Therapeutics (GANX) Buy Recommendation - Nasdaq

Dec 19, 2025

US Market Wrap: Why Gain Therapeutics Inc. stock could see breakout soonJuly 2025 Retail & Weekly High Return Forecasts - Улправда

Dec 19, 2025

Can Gain Therapeutics Inc. stock sustain institutional interestJuly 2025 News Drivers & Community Consensus Stock Picks - Улправда

Dec 19, 2025

GANX - Finviz

Dec 19, 2025

Can Gain Therapeutics Inc. stock weather global recession2025 Analyst Calls & AI Powered Buy and Sell Recommendations - Улправда

Dec 19, 2025

Published on: 2025-12-19 20:46:25 - Улправда

Dec 19, 2025

Earnings Recap: Is Gain Therapeutics Inc. stock a smart buy before Fed meetingWeekly Loss Report & Growth Focused Stock Reports - Улправда

Dec 19, 2025

Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright - MarketBeat

Dec 19, 2025

Weekly Recap: Is Gain Therapeutics Inc. stock a smart buy before Fed meetingInsider Buying & Expert Approved Trade Ideas - Улправда

Dec 19, 2025

Why Gain Therapeutics Inc. stock attracts high net worth investors2025 Risk Factors & High Return Trade Guides - DonanımHaber

Dec 19, 2025

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease - The Manila Times

Dec 19, 2025

Dec 18, 2025

Why Gain Therapeutics Inc. stock could see breakout soon2025 Investor Takeaways & Community Shared Stock Ideas - Улправда

Dec 18, 2025

Early signals stack up: Two small molecules activate GCase in Parkinson’s - biocentury.com

Dec 18, 2025

Parkinson's experts to unpack new GT-02287 biomarker data Jan. 6 - Stock Titan

Dec 18, 2025

Gain Therapeutics Reports Encouraging Phase 1b Parkinson’s Data - TipRanks

Dec 18, 2025

Gain Therapeutics Announces Phase 1b Study Results for GT-02287 - TradingView — Track All Markets

Dec 18, 2025

[8-K] Gain Therapeutics, Inc. Reports Material Event | GANX SEC FilingForm 8-K - Stock Titan

Dec 18, 2025

Gain Therapeutics Reports First-Ever Reduction of Glucosylsphingosine in CSF of Parkinson's Disease Patients in Phase 1b Study of GT-02287 - Quiver Quantitative

Dec 18, 2025

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease - The Manila Times

Dec 18, 2025

Early Parkinson's study links spinal fluid change to brain enzyme shift - Stock Titan

Dec 18, 2025

Profit Recap: Can Gain Therapeutics Inc. stock reach $100 price targetDip Buying & Weekly Return Optimization Alerts - Улправда

Dec 18, 2025

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Dec 18, 2025

Dec 14, 2025

Trade Recap: Will Atossa Therapeutics Inc stock gain from lower inflationJuly 2025 Chart Watch & Weekly Chart Analysis and Guides - moha.gov.vn

Dec 14, 2025

Dec 13, 2025

AI and Physics-Based Modeling Identifies a New Parkinson’s Disease Drug - the-scientist.com

Dec 13, 2025

Dec 11, 2025

Here's why Gain Therapeutics, Inc. (GANX) is a great momentum stock to buy - MSN

Dec 11, 2025

Dec 10, 2025

Gain Therapeutics At A Crossroads: Will GT-02287 Deliver Disease-Modifying Proof? - RTTNews

Dec 10, 2025

How sustainable is Gain Therapeutics Inc stock dividend payoutProfit Target & Consistent Growth Equity Picks - moha.gov.vn

Dec 10, 2025

Dec 08, 2025

Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy - sharewise.com

Dec 08, 2025